Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22.

Saved in:
Bibliographic Details
Title: Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22.
Authors: Robertson KC; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Amann SJ; Research Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, Vienna, Austria.; Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Liu T; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Funk AV; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Wang X; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Grishkovskaya I; Research Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, Vienna, Austria., Mehmood A; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Computational Medicine Program, University of North Carolina, Chapel Hill, NC, USA., Tabor JR; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Norris-Drouin JL; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Arrowsmith CH; Structural Genomics Consortium, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON, Canada., Collins JL; Office of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Miao Y; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.; Computational Medicine Program, University of North Carolina, Chapel Hill, NC, USA., Emanuele MJ; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Haselbach D; Research Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, Vienna, Austria. david.haselbach@imp.ac.at., James LI; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. ingerman@email.unc.edu.; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu., Brown NG; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA. nbrown1@med.unc.edu.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. nbrown1@med.unc.edu.
Source: Nature communications [Nat Commun] 2026 Apr 23; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 23.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-72235-9